NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Recurrent Glioma
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Germ Cell Tumor
Recurrent Malignant Solid Neoplasm
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Refractory Malignant Germ Cell Tumor
Refractory Rhabdomyosarcoma
Refractory Soft Tissue Sarcoma
Wilms Tumor

Interventions: Other: Pharmacokinetic Study
Drug: Ulixertinib

First Posted Date: 2018-10-09

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT03698994

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Arnold Palmer Hospital for Children, Orlando, Florida, United States
🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States

and more 105 locations

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Phase 2

Active, not recruiting

Conditions: Acral Lentiginous Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Melanoma AJCC v8
Mucosal Melanoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2018-10-05

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 313

Registration Number: NCT03698019

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 813 locations

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Phase 2

Active, not recruiting

Conditions: Lymphoproliferative Disorders
Autoimmune Lymphoproliferative
Primary T-cell Immunodeficiency Disorders
Immune System Diseases
Common Variable Immunodeficiency

Interventions: Drug: Reduced Intensity Conditioning
Drug: Immunosuppression Only Conditioning
Drug: GVHD Prophylaxis
Procedure: Allogeneic HSC

First Posted Date: 2018-09-10

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT03663933

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Marrow Donor Program, Minneapolis, Minnesota, United States

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2

Active, not recruiting

Conditions: Endometrial Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrioid Adenocarcinoma
Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Drug: Cediranib
Drug: Capivasertib
Drug: Cediranib Maleate
Biological: Durvalumab
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Olaparib
Procedure: Multigated Acquisition Scan

First Posted Date: 2018-09-07

Last Posted Date: 2025-02-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 286

Registration Number: NCT03660826

Locations: 🇺🇸
Huron Medical Center PC, Port Huron, Michigan, United States
🇺🇸
Health Partners Inc, Minneapolis, Minnesota, United States
🇺🇸
Monticello Cancer Center, Monticello, Minnesota, United States

and more 763 locations

Brain Dopamine Function in Human Obesity

Early Phase 1

Completed

Conditions: Healthy Volunteers
Obesity
Overweight

Interventions: Drug: [c11] raclopride
Drug: [18F]fallypride

First Posted Date: 2018-08-28

Last Posted Date: 2023-07-11

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 61

Registration Number: NCT03648892

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome

Phase 2

Completed

Conditions: Gastric Neoplasms
Gastric Cancer

Interventions: Device: Endoscope+Cellvizio(R) 100 microscope

First Posted Date: 2018-08-28

Last Posted Date: 2021-07-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT03648879

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2

Terminated

Conditions: Mesothelioma

Interventions: Drug: LMB-100
Biological: Pembrolizumab

First Posted Date: 2018-08-23

Last Posted Date: 2021-12-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03644550

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8
Clinical Stage IV Gastric Cancer AJCC v8
Unresectable Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastric Adenocarcinoma
Unresectable Gastric Adenocarcinoma

Interventions: Drug: Berzosertib
Procedure: Computed Tomography Assisted Biopsy
Procedure: Endoscopic Biopsy
Drug: Irinotecan
Procedure: Magnetic Resonance Imaging

First Posted Date: 2018-08-22

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT03641313

Locations: 🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 28 locations

Sunitinib in Sarcomas of the Central Nervous System

Phase 2

Terminated

Conditions: Central Nervous System Sarcoma
Gliosarcoma

Interventions: Drug: Sunitinib
Device: wGT3x-BT

First Posted Date: 2018-08-22

Last Posted Date: 2022-04-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03641326

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir

Withdrawn

Conditions: Hepatitis C Virus

First Posted Date: 2018-08-21

Last Posted Date: 2019-07-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03639207

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy